The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

March 25, 2020

Phat Le, MD, discusses the need for aggressive therapeutic approaches in oligometastatic colorectal cancer.

March 25, 2020

Kanwal Raghav, MBBS, MD, discusses treatment options in newly diagnosed metastatic colorectal cancer.

March 25, 2020

Hun Ju Lee, MD, discusses the implications of phase I results regarding the combination of carfilzomib and ibrutinib in relapsed/refractory mantle cell lymphoma.

March 24, 2020

Jason Westin, MD, MS, FACP, discusses challenges with treating patients with large cell lymphoma.

March 23, 2020

Michael J. Overman, MD, discusses second-line therapy options for patients with colorectal cancer.

March 21, 2020

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses known elements of COVID-19.

March 20, 2020

Jonathan Mizrahi, MD, discusses the goal of the phase III COMMIT trial in mismatch repair deficient colorectal cancer.

March 19, 2020

Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with oligometastatic colorectal cancer (CRC).

March 18, 2020

David S. Hong, MD, discusses the burgeoning role of multitargeted therapeutics in patients with hematologic malignancies.

March 18, 2020

Prithviraj Bose, MD, discusses the high unmet need in post-myeloproliferative neoplasms acute myeloid leukemia and the impact of findings from the phase I/II trial on current and future treatment strategies in the space.

March 18, 2020

Matthew T. Campbell, MD, MS, shares ways to prevent the spread of coronavirus 2019.

March 18, 2020

Jason Westin, MD, MS, FACP, discusses the role of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

March 17, 2020

Neeta Somaiah, MD, discusses ongoing research in the field of sarcoma.

March 16, 2020

Ruben Mesa, MD, discusses the utility of fedratinib for patients with myelofibrosis who progress on first-line ruxolitinib.

March 16, 2020

Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR, discusses the findings of the retrospective analysis of pulmonary hypertension in patients with myelofibrosis and their impact on clinical practice.

March 14, 2020

Matthew H.G. Katz, MD, FACS, discusses the eligibility criteria for up-front surgery in patients with pancreatic cancer.

March 13, 2020

Shubham Pant, MD, discusses exciting data with PARP inhibitors in pancreatic cancer.

March 13, 2020

Jason Westin, MD, MS, FACP, discusses the potential for a chemotherapy-free future in large cell lymphoma.

March 12, 2020

Ryan W. Huey, MD, discusses potential sequencing options with sorafenib among novel combination strategies in hepatocellular carcinoma.

March 12, 2020

Combination therapy with cirmtuzumab and ibrutinib induced a 50% complete response rate in the phase I/II CIRLL study.